28 /100
MEDIUM RISK
Score updated Jul 13, 2026

CLDX — Celldex Therapeutics, Inc. Dilution Risk Tracker

Track CLDX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CLDX — Get alerts when the score changes →

As of July 13, 2026, Celldex Therapeutics, Inc. (CLDX) has a DilutionWatch DilutionScore of 28/100, rated MEDIUM dilution risk. Celldex Therapeutics, Inc. has a market capitalization of $2.47B, 78.49M shares outstanding, 232 institutional holders tracked. Key dilution vectors include approximately 29 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
10
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for CLDX.
🔔 Track CLDX — Get forecast alerts →

💹 Market Data

Market Cap$2.47B
Shares Outstanding78.49M
Float72.46M
Cash$451.46M
Debt$1.91M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 8.0% shares (2026Q1 vs prior)
232 institutional holders · 80.73M shares
#1 WELLINGTON MANAGEMENT GROUP LLP 8.56M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 5.92M shares
#3 Kynam Capital Management, LP 5.84M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest7.74M
Days to Cover4.3
% of Float10.7%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

No recent SEC insights

📰 Recent News

No recent news

📋 What This Means for CLDX Shareholders

Celldex Therapeutics, Inc. (CLDX) has a DilutionScore of 28/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for CLDX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for CLDX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for CLDX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track CLDX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CLDX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for CLDX
📊 CLDX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CLDX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.